|
SunRISe-1: Phase 2b study of TAR-200 plus cetrelimab, TAR-200 alone, or cetrelimab alone in participants with high-risk nonmuscle-invasive bladder cancer unresponsive to Bacillus Calmette-Guérin who are ineligible for or decline radical cystectomy. |
|
Michiel Simon Van Der Heijden |
Stock and Other Ownership Interests - Gilead Sciences |
Consulting or Advisory Role - Astellas Pharma (Inst); AstraZeneca/MedImmune (Inst); Bristol-Myers Squibb (Inst); Janssen (Inst); MSD Oncology (Inst); Pfizer (Inst); Roche/Genentech (Inst); Seagen (Inst) |
Research Funding - 4SC (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Roche (Inst); Seagen (Inst) |
Travel, Accommodations, Expenses - Astellas Pharma; MSD Oncology; Novartis; Roche |
|
|
|
Stock and Other Ownership Interests - Johnson & Johnson |
Consulting or Advisory Role - Blue Earth Diagnostics |
Patents, Royalties, Other Intellectual Property - Taris BioMedical |
Travel, Accommodations, Expenses - Johnson & Johnson |
|
|
|
|
|
|
|
|
No Relationships to Disclose |
|
|
|
Travel, Accommodations, Expenses - Janssen |
|
|
|
|
|
Employment - Johnson & Johnson |
Stock and Other Ownership Interests - Johnson & Johnson |
|
|
|
Stock and Other Ownership Interests - AI Therapeutics; Johnson & Johnson |
Patents, Royalties, Other Intellectual Property - AI Therapeutics |
|
|
|
Stock and Other Ownership Interests - Johnson & Johnson |
|
|
Consulting or Advisory Role - Photocure; Verity Pharmaceuticals |